In this respect we offer guidance in getting through these post-transcriptional problems, which can occur with the use of any promoter.doi:10.1385/0-89603-480-1:55Daniel G. YansuraSteven H. BassMethods in Molecular BiologyBass SH, Yansura DG (2000) Application of the E. coli trp promoter...
Brevibacterium flavum is an important microorganism for the production of amino acids in industrial fermentation. Knowledge of promoters in B. flavum is essential for efficient modulation of gene expression in metabolic engineering. Here we have constructed a novel E. coli-B. flavum promoter-probe vec...
such as a liposome, a microsome, or a cell, of which the last one is preferred. The last one is preferred, because a cell may provide other components of a suitable environment, such as signalling pathways and the like.
4. The anti-Claudin 18.2 antibody according to claim 1, comprising a heavy chain variable region and a light chain variable region, wherein: v) the amino acid sequence of the heavy chain variable region has at least 90% identity to SEQ ID NO: 3 or 24, and the amino acid sequence of ...
coli lac or trp promoter; λ phage PL promoter; eukaryotic promoters include CMV immediate early promoter, HSV thymidine kinase promoter, early and late SV40 promoter, retrovirus LTR, and some other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses....
pastoris strains for heterologous protein expression, we designed two expression vectors, pGLY10969 and pGLY10970 encoding the protein sequences for the light-chain and the heavy-chain of an anti-HER2 antibody, respectively. Their expressions are under the control of the AOX1 promoter and TEF ...
The present invention relates to new antibody-drug conjugates (ADCs) targeting DLK1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in producti
β-amylase (EC 3.2.1.2) is an exo-enzyme that shows high specificity for cleaving the α-1,4-glucosidic linkage of starch from the non-reducing end, thereby liberating maltose. In this study, we heterologously expressed and characterized a novel β-amyla
Their expressions are under the con- trol of the AOX1 promoter and TEF transcriptional terminator (Figure 1a and 1b). To ensure the mating, two dominant selection markers are used, where plasmid pGLY10969 uses the S. cerevisiae ARR3 gene (ARS, con- fers resistance to...
The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the phar...